89288-22-2

Basic information

• Product Name: (S)-2-AMino-3-(4-nitrophenyl)propanol
• Synonyms: (S)-2-AMino-3-(4-nitrophenyl)propanol;(S)-b-AMino-4-nitrobenzenepropanol;(2S)-2-AMino-3-(4-nitrophenyl)-1-propanol;(2S)-2-amino-3-(4-nitrophenyl)propan-1-ol
• CAS NO: 89288-22-2
• Molecular Formula: C₉H₁₂N₂O₃
• Molecular Weight: 196.20318
• Mol File: 89288-22-2.mol
• Article Data: 22

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (S)-2-AMino-3-(4-nitrophenyl)propanol(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-AMino-3-(4-nitrophenyl)propanol(89288-22-2)
• EPA Substance Registry System: (S)-2-AMino-3-(4-nitrophenyl)propanol(89288-22-2)

Safety Data

• Hazardous Substances Data: 89288-22-2(Hazardous Substances Data)

Usage

Description

(S)-2-AMino-3-(4-nitrophenyl)propanol is a chiral organic compound with the molecular formula C9H11NO3. It is characterized by the presence of an amino group (-NH2) at the 2nd carbon, a 4-nitrophenyl group attached to the 3rd carbon, and a hydroxyl group (-OH) at the same 3rd carbon. The "S" configuration indicates that the molecule has a specific three-dimensional arrangement of these functional groups, which is crucial for its properties and applications.

Uses

Used in Pharmaceutical Industry:
(S)-2-AMino-3-(4-nitrophenyl)propanol is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows it to serve as a building block for the development of new drugs with potential therapeutic applications.
Used in the Synthesis of 2-Substituted Thiazole Carboxamides:
In the field of medicinal chemistry, (S)-2-AMino-3-(4-nitrophenyl)propanol is utilized in the preparation of a new series of 2-substituted thiazole carboxamides. These compounds have been identified as potent inhibitors of Akt kinases, which are important targets for the treatment of various diseases, including cancer and metabolic disorders. By inhibiting Akt kinases, these thiazole carboxamides can modulate cellular signaling pathways and potentially lead to the development of effective therapeutic agents.

Upstream product

• 114346-29-1 tert-butyl N-[(2S)-1-hydroxy-3-(4-nitrophenyl)propan-2-yl]carbamate 
• 6265-86-7 formylamino-(4-nitro-benzyl)-malonic acid diethyl ester 
• 1991-83-9 4-nitrophenylalanine 
• 55895-91-5 ethyl 2-amino-3-(4-nitrophenyl) propanoate 
• 33305-77-0 Boc-Phe(p-NO₂)-OH 
• 63-91-2 L-phenylalanine 
• 100616-58-8 (R or S)-1-acetoxy-2-acetylamino-3-(4-nitro-phenyl)-propane 
• 17193-40-7 (S)-4-nitrophenylalanine methyl ester hydrochloride 
• 81677-60-3 (L)-p-Nitrophenylalanine methyl ester 
• 949-99-5 4-nitro-3-phenyl-L-alanine 
• 65615-89-6 methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(4-nitrophenyl)propanoate 
• 34276-53-4 ethyl (S)-2-amino-3-(4-nitrophenyl)propionate 
• 85317-52-8 methyl 2-amino-3-(4-nitrophenyl)propionate 

Downstream Products

• 139264-55-4 (S)-4-(4'-nitrobenzyl)-1,3-oxazolidin-2-one 
• 183669-13-8 tert-butyl (1-hydroxy-3-(4-nitrophenyl)propan-2-yl)carbamate 
• 1610608-12-2 (S)-3-((1S,2R)-1,2-diethyl-2-vinylcyclopropanecarbonyl)-4-(4-nitrobenzyl)oxazolidin-2-one 
• 1610608-07-5 (S)-3-((1R,2S)-1,2-diethyl-2-vinylcyclopropanecarbonyl)-4-(4-nitrobenzyl)oxazolidin-2-one 
• 326019-69-6 dichloroacetic acid-[(R or S)-1-hydroxymethyl-2-(4-nitro-phenyl)-ethylamide] 
• 1599422-74-8 tert-butyl 2-{[(2,4-dimethoxyphenyl)methyl][(2S)-1-hydroxy-3-(4-nitrophenyl)propan-2-yl]amino}acetate 
• 1599422-73-7 tert-butyl 2-{(benzyl)[(2S)-1-hydroxy-3-(4-nitrophenyl)propan-2-yl]-amino}acetate 
• 1599422-72-6 (2S)-2-{[(2,4-dimethoxyphenyl)methyl]amino}-3-(4-nitrophenyl)-propan-1-ol 
• 406164-95-2 (2S)-2-(benzylamino)-3-(4-nitrophenyl)propan-1-ol 
• 114346-29-1 tert-butyl N-[(2S)-1-hydroxy-3-(4-nitrophenyl)propan-2-yl]carbamate 
• 1353022-71-5 N-[2-chloro-3-(4-nitrophenyl)propyl]-4-methylbenzene-1-sulfonamide 
• 1353022-70-4 1-[(4-methylphenyl)sulfonyl]-2-[(4-nitrophenyl)methyl]aziridine 
• 92966-95-5 2-Benzylidenamino-3-(p-nitrophenyl)-1-propanol 
• 1353022-72-6 N-(1-{4,7-bis[(4-methylphenyl)sulfonyl]-1,4,7-triazonan-1-yl}-3-(4-nitrophenyl)propan-2-yl)-4-methylbenzene-1-sulfonamide 

Relevant articles and documents

Synthesis of Water-Soluble Chiral DOTA Lanthanide Complexes with Predominantly Twisted Square Antiprism Isomers and Circularly Polarized Luminescence

One-step cyclization of a tetraazamacrocycle 5 with 70% yield in a 25-g scale was performed. Its chiral DOTA derivatives, L4, has ?93% of TSAP coordination isomer in its Eu(III) and Yb(III) complexes in aqueous solution. [GdL4]5- exhibits a high relaxivity, making it a promising and efficient MRI contrast agent. High luminescence dissymmetry factor (glum) values of 0.285 (ΔJ = 1) for [TbL3]- and 0.241 (ΔJ = 1) for [TbL4]5- in buffer solutions were recorded.

ANTIBODY DRUG CONJUGATES

This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments, particularly antibody drug conjugates comprising anti-P-cadherin antibodies conjugated to auristatin analogs. The invention also relates to methods of treating cancer using the antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY

Described herein are compounds, compositions, and methods for diagnosing and/or monitoring pathogenic disease using positron emission tomography. Also described are conjugates of the formula B-L-P, wherein B is a radical of a targeting agent selected from vitamin receptor binding ligands (such as folate), PSMA binding ligands, or PSMA inhibitors; L is a divalent linker comprising aspartic acid, lysine, or arginine, and P is a radical of an imaging agent or radiotherapy agent, such as a radionuclide or radionuclide containing group, or a radical of a compound capable of binding a radionuclide, such as a metal chelating group.